Excretion of sodium 2-mercaptoethanesulphonate (MESNA) in the urine of volunteers after oral dosing.
Sodium 2-mercaptoethanesulphonate (MESNA) is a uroprotective agent generally given i.v. to prevent haemorrhagic cystitis during oxazaphosphorine cancer chemotherapy. Oral administration of the drug is described since this might be an important route during long-term oxazaphosphorine treatment. MESNA is absorbed from the GI tract and excreted in the urine (about 41.5% of the dose), peak excretion being 2-3 hr after administration. A proportion of the excreted dose is as free thiols (about 24.2%) and the remainder is as disulphides. MESNA is shown to enhance excretion of cysteine in urine.
D000284:Administration, Oral; D000328:Adult; D003545:Cysteine / Q000652:urine; D004220:Disulfides / Q000652:urine; D006801:Humans; D008297:Male; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use / Q000652:urine*; D013438:Sulfhydryl Compounds / Q000652:urine; D001745:Urinary Bladder Diseases / Q000517:prevention & control
D004220:Disulfides; D013438:Sulfhydryl Compounds; D008623:Mercaptoethanol; D003545:Cysteine; D015080:Mesna